Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 732

1.

Antibody targeting TSPAN12/β-catenin signaling in vasoproliferative retinopathy.

Bucher F, Friedlander M, Yea K.

Oncotarget. 2017 Dec 18;9(16):12538-12539. doi: 10.18632/oncotarget.23401. eCollection 2018 Feb 27. No abstract available.

2.

Paternal high-fat diet enhances offspring whole-body insulin sensitivity and skeletal muscle insulin signaling early in life.

Consitt LA, Saxena G, Slyvka Y, Clark BC, Friedlander M, Zhang Y, Nowak FV.

Physiol Rep. 2018 Mar;6(5). doi: 10.14814/phy2.13583.

3.

Defining the Most Appropriate Primary End Point in Phase 2 Trials of Immune Checkpoint Inhibitors for Advanced Solid Cancers: A Systematic Review and Meta-analysis.

Ritchie G, Gasper H, Man J, Lord S, Marschner I, Friedlander M, Lee CK.

JAMA Oncol. 2018 Apr 1;4(4):522-528. doi: 10.1001/jamaoncol.2017.5236.

PMID:
29470579
4.

Expression III: patients' expectations and preferences regarding physician-patient relationship and clinical management-results of the international NOGGO/ENGOT-ov4-GCIG study in 1830 ovarian cancer patients from European countries.

Oskay-Özcelik G, Alavi S, Richter R, Keller M, Chekerov R, Cecere SC, Cormio G, Joly F, Kurtz JE, du Bois A, Maciejewski M, Jedryka M, Vergote I, Van Nieuwenhuysen E, Casado A, Mendiola C, Achimas-Cadariu P, Vlad C, Reimer D, Zeimet AG, Friedlander M, Sehouli J.

Ann Oncol. 2018 Apr 1;29(4):910-916. doi: 10.1093/annonc/mdy037.

PMID:
29415128
5.

Exploring knowledge, attitudes and experience of genitourinary symptoms in women with early breast cancer on adjuvant endocrine therapy.

Sousa M, Peate M, Lewis C, Jarvis S, Willis A, Hickey M, Friedlander M.

Eur J Cancer Care (Engl). 2018 Mar;27(2):e12820. doi: 10.1111/ecc.12820. Epub 2018 Jan 16.

PMID:
29337398
6.

Quality of life in patients with advanced epithelial ovarian cancer (EOC) randomized to maintenance pazopanib or placebo after first-line chemotherapy in the AGO-OVAR 16 trial. Measuring what matters-patient-centered end points in trials of maintenance therapy.

Friedlander M, Rau J, Lee CK, Meier W, Lesoin A, Kim JW, Poveda A, Buck M, Scambia G, Shimada M, Hilpert F, King MT, Debruyne P, Bologna A, Malander S, Monk BJ, Petru E, Calvert P, Herzog TJ, Barrett C, du Bois A.

Ann Oncol. 2018 Mar 1;29(3):737-743. doi: 10.1093/annonc/mdx796.

PMID:
29267856
7.

Fully automated, deep learning segmentation of oxygen-induced retinopathy images.

Xiao S, Bucher F, Wu Y, Rokem A, Lee CS, Marra KV, Fallon R, Diaz-Aguilar S, Aguilar E, Friedlander M, Lee AY.

JCI Insight. 2017 Dec 21;2(24). pii: 97585. doi: 10.1172/jci.insight.97585. [Epub ahead of print]

8.

Measuring what matters MOST: validation of the Measure of Ovarian Symptoms and Treatment, a patient-reported outcome measure of symptom burden and impact of chemotherapy in recurrent ovarian cancer.

King MT, Stockler MR, O'Connell RL, Buizen L, Joly F, Lanceley A, Hilpert F, Okamoto A, Aotani E, Bryce J, Donnellan P, Oza A, Avall-Lundqvist E, Berek JS, Sehouli J, Feeney A, Berton-Rigaud D, Costa DSJ, Friedlander ML; GCIG Symptom Benefit group.

Qual Life Res. 2018 Jan;27(1):59-74. doi: 10.1007/s11136-017-1729-8. Epub 2017 Dec 16.

PMID:
29248998
9.

Global Connections to Study Idiopathic Macular Telangiectasia Type 2.

Chew EY, Friedlander M.

Retina. 2018 Jan;38 Suppl 1:S3-S7. doi: 10.1097/IAE.0000000000001921. No abstract available.

PMID:
29190235
10.

Letrozole may be a valuable maintenance treatment in high-grade serous ovarian cancer patients.

Heinzelmann-Schwarz V, Knipprath Mészaros A, Stadlmann S, Jacob F, Schoetzau A, Russell K, Friedlander M, Singer G, Vetter M.

Gynecol Oncol. 2018 Jan;148(1):79-85. doi: 10.1016/j.ygyno.2017.10.036. Epub 2017 Nov 20.

11.

A Systematic Review of Health-Related Quality of Life Reporting in Ovarian Cancer Phase III Clinical Trials: Room to Improve.

Wilson MK, Friedlander ML, Joly F, Oza AM.

Oncologist. 2018 Feb;23(2):203-213. doi: 10.1634/theoncologist.2017-0297. Epub 2017 Nov 8. Review.

PMID:
29118265
12.

Clinical and genetic predictors of paclitaxel neurotoxicity based on patient- versus clinician-reported incidence and severity of neurotoxicity in the ICON7 trial.

Park SB, Kwok JB, Asher R, Lee CK, Beale P, Selle F, Friedlander M.

Ann Oncol. 2017 Nov 1;28(11):2733-2740. doi: 10.1093/annonc/mdx491.

PMID:
29117336
13.

Validation of the modified Glasgow Prognostic Score (mGPS) in recurrent ovarian cancer (ROC) - Analysis of patients enrolled in the GCIG Symptom Benefit Study (SBS).

Roncolato FT, Berton-Rigaud D, O'Connell R, Lanceley A, Sehouli J, Buizen L, Okamoto A, Aotani E, Lorusso D, Donnellan P, Oza A, Avall-Lundqvist E, Berek J, Hilpert F, Ledermann JA, Kaminsky MC, Stockler MR, King MT, Friedlander M.

Gynecol Oncol. 2018 Jan;148(1):36-41. doi: 10.1016/j.ygyno.2017.10.019. Epub 2017 Oct 26.

PMID:
29107348
14.

Novel Modification of HistoGel-Based Cell Block Preparation Method: Improved Sufficiency for Molecular Studies.

Rekhtman N, Buonocore DJ, Rudomina D, Friedlander M, Dsouza C, Aggarwal G, Arcila M, Edelweiss M, Lin O.

Arch Pathol Lab Med. 2018 Apr;142(4):529-535. doi: 10.5858/arpa.2017-0030-OA. Epub 2017 Nov 2.

PMID:
29095036
15.

Homologous Recombination DNA Repair Pathway Disruption and Retinoblastoma Protein Loss Are Associated with Exceptional Survival in High-Grade Serous Ovarian Cancer.

Garsed DW, Alsop K, Fereday S, Emmanuel C, Kennedy CJ, Etemadmoghadam D, Gao B, Gebski V, Garès V, Christie EL, Wouters MCA, Milne K, George J, Patch AM, Li J, Arnau GM, Semple T, Gadipally SR, Chiew YE, Hendley J, Mikeska T, Zapparoli GV, Amarasinghe K, Grimmond SM, Pearson JV, Waddell N, Hung J, Stewart CJR, Sharma R, Allan PE, Rambau PF, McNally O, Mileshkin L, Hamilton A, Ananda S, Grossi M, Cohen PA, Leung YC, Rome RM, Beale P, Blomfield P, Friedlander M, Brand A, Dobrovic A, Köbel M, Harnett P, Nelson BH, Bowtell DDL, deFazio A; Nadia Traficante, for the Australian Ovarian Cancer Study Group.

Clin Cancer Res. 2018 Feb 1;24(3):569-580. doi: 10.1158/1078-0432.CCR-17-1621. Epub 2017 Oct 23.

PMID:
29061645
16.

Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer: randomized phase II study.

Han HS, Diéras V, Robson M, Palácová M, Marcom PK, Jager A, Bondarenko I, Citrin D, Campone M, Telli ML, Domchek SM, Friedlander M, Kaufman B, Garber JE, Shparyk Y, Chmielowska E, Jakobsen EH, Kaklamani V, Gradishar W, Ratajczak CK, Nickner C, Qin Q, Qian J, Shepherd SP, Isakoff SJ, Puhalla S.

Ann Oncol. 2018 Jan 1;29(1):154-161. doi: 10.1093/annonc/mdx505.

PMID:
29045554
17.

Signatures of positive selection reveal a universal role of chromatin modifiers as cancer driver genes.

Zapata L, Susak H, Drechsel O, Friedländer MR, Estivill X, Ossowski S.

Sci Rep. 2017 Oct 13;7(1):13124. doi: 10.1038/s41598-017-12888-1.

18.

Correlation Between Macular Integrity Assessment and Optical Coherence Tomography Imaging of Ellipsoid Zone in Macular Telangiectasia Type 2.

Mukherjee D, Lad EM, Vann RR, Jaffe SJ, Clemons TE, Friedlander M, Chew EY, Jaffe GJ, Farsiu S; MacTel Study Group.

Invest Ophthalmol Vis Sci. 2017 May 1;58(6):BIO291-BIO299. doi: 10.1167/iovs.17-21834.

PMID:
28973315
19.

Differential Impact of Glucose Administered Intravenously and Orally on Circulating miR-375 Levels in Human Subjects.

Yan X, Wang Z, Westberg-Rasmussen S, Tarbier M, Rathjen T, Tattikota SG, Peck BCE, Kanke M, Oxvig C, Frystyk J, Starup-Linde J, Sethupathy P, Friedländer MR, Gregersen S, Poy MN.

J Clin Endocrinol Metab. 2017 Oct 1;102(10):3749-3755. doi: 10.1210/jc.2017-01365.

PMID:
28973164
20.

The acute effects of ultraviolet radiation on the blood transcriptome are independent of plasma 25OHD3.

Bustamante M, Hernandez-Ferrer C, Sarria Y, Harrison GI, Nonell L, Kang W, Friedländer MR, Estivill X, González JR, Nieuwenhuijsen M, Young AR.

Environ Res. 2017 Nov;159:239-248. doi: 10.1016/j.envres.2017.07.045. Epub 2017 Sep 18.

PMID:
28822308
21.

Risk of uterine cancer for BRCA1 and BRCA2 mutation carriers.

Lee YC, Milne RL, Lheureux S, Friedlander M, McLachlan SA, Martin KL, Bernardini MQ, Smith C, Picken S, Nesci S, Hopper JL, Phillips KA; Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer (kConFab).

Eur J Cancer. 2017 Oct;84:114-120. doi: 10.1016/j.ejca.2017.07.004. Epub 2017 Aug 10.

PMID:
28802188
22.

Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial.

Pujade-Lauraine E, Ledermann JA, Selle F, Gebski V, Penson RT, Oza AM, Korach J, Huzarski T, Poveda A, Pignata S, Friedlander M, Colombo N, Harter P, Fujiwara K, Ray-Coquard I, Banerjee S, Liu J, Lowe ES, Bloomfield R, Pautier P; SOLO2/ENGOT-Ov21 investigators.

Lancet Oncol. 2017 Sep;18(9):1274-1284. doi: 10.1016/S1470-2045(17)30469-2. Epub 2017 Jul 25.

PMID:
28754483
23.

Inflammatory Myofibroblastic Tumors of the Female Genital Tract Are Under-recognized: A Low Threshold for ALK Immunohistochemistry Is Required.

Pickett JL, Chou A, Andrici JA, Clarkson A, Sioson L, Sheen A, Reagh J, Najdawi F, Kim Y, Riley D, Maidens J, Nevell D, McIlroy K, Valmadre S, Gard G, Hogg R, Turchini J, Robertson G, Friedlander M, Gill AJ.

Am J Surg Pathol. 2017 Oct;41(10):1433-1442. doi: 10.1097/PAS.0000000000000909.

24.

Resisting RECIST-Uniformity Versus Clinical Validity.

Wilson MK, Friedlander ML, Lheureux S, Small W Jr, Poveda A, Pujade-Lauraine E, Karakasis K, Bacon M, Bowering V, Chawla T, Oza AM.

Int J Gynecol Cancer. 2017 Oct;27(8):1619-1627. doi: 10.1097/IGC.0000000000001062.

PMID:
28692635
25.

Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers.

Kuchenbaecker KB, Hopper JL, Barnes DR, Phillips KA, Mooij TM, Roos-Blom MJ, Jervis S, van Leeuwen FE, Milne RL, Andrieu N, Goldgar DE, Terry MB, Rookus MA, Easton DF, Antoniou AC; BRCA1 and BRCA2 Cohort Consortium, McGuffog L, Evans DG, Barrowdale D, Frost D, Adlard J, Ong KR, Izatt L, Tischkowitz M, Eeles R, Davidson R, Hodgson S, Ellis S, Nogues C, Lasset C, Stoppa-Lyonnet D, Fricker JP, Faivre L, Berthet P, Hooning MJ, van der Kolk LE, Kets CM, Adank MA, John EM, Chung WK, Andrulis IL, Southey M, Daly MB, Buys SS, Osorio A, Engel C, Kast K, Schmutzler RK, Caldes T, Jakubowska A, Simard J, Friedlander ML, McLachlan SA, Machackova E, Foretova L, Tan YY, Singer CF, Olah E, Gerdes AM, Arver B, Olsson H.

JAMA. 2017 Jun 20;317(23):2402-2416. doi: 10.1001/jama.2017.7112.

PMID:
28632866
26.

Reducing Uncertainty: Predictors of Stopping Chemotherapy Early and Shortened Survival Time in Platinum Resistant/Refractory Ovarian Cancer-The GCIG Symptom Benefit Study.

Roncolato FT, Joly F, O'Connell R, Lanceley A, Hilpert F, Buizen L, Okamoto A, Aotani E, Pignata S, Donnellan P, Oza A, Avall-Lundqvist E, Berek JS, Heitz F, Feeney A, Berton-Rigaud D, Stockler MR, King M, Friedlander M; GCIG Symptom Benefit group.

Oncologist. 2017 Sep;22(9):1117-1124. doi: 10.1634/theoncologist.2017-0047. Epub 2017 Jun 8.

PMID:
28596446
27.

Quality of life predicts overall survival in women with platinum-resistant ovarian cancer: an AURELIA substudy.

Roncolato FT, Gibbs E, Lee CK, Asher R, Davies LC, Gebski VJ, Friedlander M, Hilpert F, Wenzel L, Stockler MR, King M, Pujade-Lauraine E.

Ann Oncol. 2017 Aug 1;28(8):1849-1855. doi: 10.1093/annonc/mdx229.

PMID:
28595285
28.

Secondary Somatic Mutations Restoring RAD51C and RAD51D Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma.

Kondrashova O, Nguyen M, Shield-Artin K, Tinker AV, Teng NNH, Harrell MI, Kuiper MJ, Ho GY, Barker H, Jasin M, Prakash R, Kass EM, Sullivan MR, Brunette GJ, Bernstein KA, Coleman RL, Floquet A, Friedlander M, Kichenadasse G, O'Malley DM, Oza A, Sun J, Robillard L, Maloney L, Bowtell D, Giordano H, Wakefield MJ, Kaufmann SH, Simmons AD, Harding TC, Raponi M, McNeish IA, Swisher EM, Lin KK, Scott CL; AOCS Study Group.

Cancer Discov. 2017 Sep;7(9):984-998. doi: 10.1158/2159-8290.CD-17-0419. Epub 2017 Jun 6.

29.

Cytologic assessment of estrogen receptor, progesterone receptor, and HER2 status in metastatic breast carcinoma.

Pareja F, Murray MP, Jean RD, Konno F, Friedlander M, Lin O, Edelweiss M.

J Am Soc Cytopathol. 2017 Jan-Feb;6(1):33-40. doi: 10.1016/j.jasc.2016.10.001.

30.

Randomized Evaluation of Cognitive-Behavioral Therapy and Graded Exercise Therapy for Post-Cancer Fatigue.

Sandler CX, Goldstein D, Horsfield S, Bennett BK, Friedlander M, Bastick PA, Lewis CR, Segelov E, Boyle FM, Chin MTM, Webber K, Barry BK, Lloyd AR.

J Pain Symptom Manage. 2017 Jul;54(1):74-84. doi: 10.1016/j.jpainsymman.2017.03.015. Epub 2017 May 11.

PMID:
28502786
31.

Paragon (ANZGOG-0903): Phase 2 Study of Anastrozole in Women With Estrogen or Progesterone Receptor-Positive Platinum-Resistant or -Refractory Recurrent Ovarian Cancer.

Bonaventura A, OʼConnell RL, Mapagu C, Beale PJ, McNally OM, Mileshkin LR, Grant PT, Hadley AM, Goh JCH, Sjoquist KM, Martyn J, DeFazio A, Scurry J, Friedlander ML; Paragon Investigators.

Int J Gynecol Cancer. 2017 Jun;27(5):900-906. doi: 10.1097/IGC.0000000000000978.

PMID:
28498256
32.

A clinical guide to the management of genitourinary symptoms in breast cancer survivors on endocrine therapy.

Sousa MS, Peate M, Jarvis S, Hickey M, Friedlander M.

Ther Adv Med Oncol. 2017 Apr;9(4):269-285. doi: 10.1177/1758834016687260. Epub 2017 Jan 31. Review.

33.

Baseline clinical predictors of antitumor response to the PARP inhibitor olaparib in germline BRCA1/2 mutated patients with advanced ovarian cancer.

Rafii S, Gourley C, Kumar R, Geuna E, Ern Ang J, Rye T, Chen LM, Shapira-Frommer R, Friedlander M, Matulonis U, De Greve J, Oza AM, Banerjee S, Molife LR, Gore ME, Kaye SB, Yap TA.

Oncotarget. 2017 Jul 18;8(29):47154-47160. doi: 10.18632/oncotarget.17005.

34.

Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: Recommendations on incorporating patient-reported outcomes in clinical trials in epithelial ovarian cancer.

Joly F, Hilpert F, Okamoto A, Stuart G, Ochiai K, Friedlander M; of the participants of the 5th Ovarian Cancer Consensus Conference.

Eur J Cancer. 2017 Jun;78:133-138. doi: 10.1016/j.ejca.2017.03.019. Epub 2017 Apr 25.

PMID:
28448857
35.

Erratum to: The patient-reported outcome content of international ovarian cancer randomised controlled trial protocols.

Mercieca-Bebber R, Friedlander M, Kok PS, Calvert M, Kyte D, Stockler M, King MT.

Qual Life Res. 2017 Aug;26(8):2249-2250. doi: 10.1007/s11136-017-1578-5. No abstract available.

PMID:
28434060
36.

Traceback: A Proposed Framework to Increase Identification and Genetic Counseling of BRCA1 and BRCA2 Mutation Carriers Through Family-Based Outreach.

Samimi G, Bernardini MQ, Brody LC, Caga-Anan CF, Campbell IG, Chenevix-Trench G, Couch FJ, Dean M, de Hullu JA, Domchek SM, Drapkin R, Spencer Feigelson H, Friedlander M, Gaudet MM, Harmsen MG, Hurley K, James PA, Kwon JS, Lacbawan F, Lheureux S, Mai PL, Mechanic LE, Minasian LM, Myers ER, Robson ME, Ramus SJ, Rezende LF, Shaw PA, Slavin TP, Swisher EM, Takenaka M, Bowtell DD, Sherman ME.

J Clin Oncol. 2017 Jul 10;35(20):2329-2337. doi: 10.1200/JCO.2016.70.3439. Epub 2017 Apr 11.

PMID:
28398847
37.

Germline Mutations in the Kallikrein 6 Region and Predisposition for Aggressive Prostate Cancer.

Briollais L, Ozcelik H, Xu J, Kwiatkowski M, Lalonde E, Sendorek DH, Fleshner NE, Recker F, Kuk C, Olkhov-Mitsel E, Savas S, Hanna S, Juvet T, Hunter GA, Friedlander M, Li H, Chadwick K, Prassas I, Soosaipillai A, Randazzo M, Trachtenberg J, Toi A, Shiah YJ, Fraser M, van der Kwast T, Bristow RG, Bapat B, Diamandis EP, Boutros PC, Zlotta AR.

J Natl Cancer Inst. 2017 Apr 1;109(4). doi: 10.1093/jnci/djw258.

PMID:
28376164
38.

Special Commentary: Early Clinical Development of Cell Replacement Therapy: Considerations for the National Eye Institute Audacious Goals Initiative.

Levin LA, Miller JW, Zack DJ, Friedlander M, Smith LEH.

Ophthalmology. 2017 Jul;124(7):926-934. doi: 10.1016/j.ophtha.2017.02.017. Epub 2017 Mar 29. Review.

39.

Antibody-Mediated Inhibition of Tspan12 Ameliorates Vasoproliferative Retinopathy Through Suppression of β-Catenin Signaling.

Bucher F, Zhang D, Aguilar E, Sakimoto S, Diaz-Aguilar S, Rosenfeld M, Zha Z, Zhang H, Friedlander M, Yea K.

Circulation. 2017 Jul 11;136(2):180-195. doi: 10.1161/CIRCULATIONAHA.116.025604. Epub 2017 Mar 29.

PMID:
28356444
40.

The safety and efficacy of controlled ovarian hyperstimulation for fertility preservation in women with early breast cancer: a systematic review.

Rodgers RJ, Reid GD, Koch J, Deans R, Ledger WL, Friedlander M, Gilchrist RB, Walters KA, Abbott JA.

Hum Reprod. 2017 May 1;32(5):1033-1045. doi: 10.1093/humrep/dex027. Review.

PMID:
28333356
41.

Improved quality of risk-reducing salpingo-oophorectomy in Australasian women at high risk of pelvic serous cancer.

Lee YC, Bressel M, Grant P, Russell P, Smith C, Picken S, Camm S, Kiely BE, Milne RL, McLachlan SA, Hickey M, Friedlander ML, Hopper JL, Phillips KA; Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer (kConFab).

Fam Cancer. 2017 Oct;16(4):461-469. doi: 10.1007/s10689-017-9977-x.

42.

Genome-wide analyses identify common variants associated with macular telangiectasia type 2.

Scerri TS, Quaglieri A, Cai C, Zernant J, Matsunami N, Baird L, Scheppke L, Bonelli R, Yannuzzi LA, Friedlander M; MacTel Project Consortium, Egan CA, Fruttiger M, Leppert M, Allikmets R, Bahlo M.

Nat Genet. 2017 Apr;49(4):559-567. doi: 10.1038/ng.3799. Epub 2017 Feb 27.

PMID:
28250457
43.

Factors associated with deciding between risk-reducing salpingo-oophorectomy and ovarian cancer screening among high-risk women enrolled in GOG-0199: An NRG Oncology/Gynecologic Oncology Group study.

Mai PL, Piedmonte M, Han PK, Moser RP, Walker JL, Rodriguez G, Boggess J, Rutherford TJ, Zivanovic O, Cohn DE, Thigpen JT, Wenham RM, Friedlander ML, Hamilton CA, Bakkum-Gamez J, Olawaiye AB, Hensley ML, Greene MH, Huang HQ, Wenzel L.

Gynecol Oncol. 2017 Apr;145(1):122-129. doi: 10.1016/j.ygyno.2017.02.008. Epub 2017 Feb 10.

44.

CD44 expression in endothelial colony-forming cells regulates neurovascular trophic effect.

Sakimoto S, Marchetti V, Aguilar E, Lee K, Usui Y, Murinello S, Bucher F, Trombley JK, Fallon R, Wagey R, Peters C, Scheppke EL, Westenskow PD, Friedlander M.

JCI Insight. 2017 Jan 26;2(2):e89906. doi: 10.1172/jci.insight.89906.

45.

70-Gene Signature in Early-Stage Breast Cancer.

Thewes B, Prins J, Friedlander M.

N Engl J Med. 2016 Dec 1;375(22):2199-2200. doi: 10.1056/NEJMc1612048. No abstract available.

PMID:
28117957
46.

A Fluorophore Fusion Construct of Human Profilin I with Non-Compromised Poly(L-Proline) Binding Capacity Suitable for Imaging.

Nejedla M, Li Z, Masser AE, Biancospino M, Spiess M, Mackowiak SD, Friedländer MR, Karlsson R.

J Mol Biol. 2017 Apr 7;429(7):964-976. doi: 10.1016/j.jmb.2017.01.004. Epub 2017 Jan 8.

PMID:
28077285
47.

Survey of 800+ data sets from human tissue and body fluid reveals xenomiRs are likely artifacts.

Kang W, Bang-Berthelsen CH, Holm A, Houben AJ, Müller AH, Thymann T, Pociot F, Estivill X, Friedländer MR.

RNA. 2017 Apr;23(4):433-445. doi: 10.1261/rna.059725.116. Epub 2017 Jan 6.

48.

A systematic evaluation of compliance and reporting of patient-reported outcome endpoints in ovarian cancer randomised controlled trials: implications for generalisability and clinical practice.

Mercieca-Bebber R, Friedlander M, Calvert M, Stockler M, Kyte D, Kok PS, King MT.

J Patient Rep Outcomes. 2017;1(1):5. doi: 10.1186/s41687-017-0008-3. Epub 2017 Oct 4.

49.

Chemotherapy for epithelial ovarian, fallopian tube and primary peritoneal cancer.

Webber K, Friedlander M.

Best Pract Res Clin Obstet Gynaecol. 2017 May;41:126-138. doi: 10.1016/j.bpobgyn.2016.11.004. Epub 2016 Nov 23. Review.

PMID:
28027849
50.

Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: recurrent disease.

Wilson MK, Pujade-Lauraine E, Aoki D, Mirza MR, Lorusso D, Oza AM, du Bois A, Vergote I, Reuss A, Bacon M, Friedlander M, Gallardo-Rincon D, Joly F, Chang SJ, Ferrero AM, Edmondson RJ, Wimberger P, Maenpaa J, Gaffney D, Zang R, Okamoto A, Stuart G, Ochiai K; participants of the Fifth Ovarian Cancer Consensus Conference.

Ann Oncol. 2017 Apr 1;28(4):727-732. doi: 10.1093/annonc/mdw663.

PMID:
27993805

Supplemental Content

Loading ...
Support Center